Possibly hazardous chemical substances and mixtures need to be clearly and correctly classified and labelled, in order for their hazards to be properly identified and communicated. As dermatologists may encounter cases of harm to patients induced by chemicals, such as chemical burns, and irritant and allergic contact dermatitis, it is essential for them to be aware of the EU CLP Regulation and its potential pitfalls. Manufacturers are required by CLP to classify their products according to the rules given in the CLP Regulation. The enforcement duty lies with the Member States and their competent authorities. Dangerous non-food consumer products have to be reported to the European Commission to be entered into the Rapid Alert System for Dangerous Non-food Products (RAPEX) notifications. The sheer complexity of the CLP Regulation and lack of awareness of its ramifications by companies, competent authorities, consumer associations and the public at large may prevent efficient enforcement actions. When dermatologists become aware of inappropriately labelled chemicals, they should inform the competent authorities.
Regulation of Chemicals in the EU Including the CLP Regulation
The regulation of chemicals in the EU has not been very systematic. A recent article mentioned 156 separate pieces of current EU legislation that concern the control and use of chemicals (7) . However, the most important components of the current EU legislation on chemicals are the REACH Regulation and the CLP Regulation.
The REACH Regulation (8) entered into force on 1 June 2007, and introduced a new system for controlling chemicals across the EU. The CLP Regulation (9) amended the REACH Regulation, entered into force 20 January 2009, and repealed Directives 67/548/EEC and 1999/45/EC on 1 June 2015. It was intended to implement the Globally Harmonized System of Classification and Labelling of Chemicals (GHS) developed within the United Nations, thus enabling a worldwide consistent system of chemical classification and labelling. With 426 915 words, it is a large piece of legislation, and this in itself may be a barrier to implementation by companies as dutyholders under the CLP Regulation.
As stated in its preamble, the aim of the CLP Regulation is twofold: first, to ensure a high level of protection of human health and the environment; and second, to ensure the free movement of chemical substances, mixtures and certain specific articles, while enhancing competitiveness and innovation.
The CLP Regulation consists of 62 articles, followed by seven annexes. Annex I contains the classification and labelling requirements for hazardous substances and mixtures, starting with general principles and then specifying classification requirements for physical hazards, health hazards, environmental hazards, and an additional EU hazard class (hazardous to the ozone layer). Annex II contains the special rules for labelling and packaging of certain substances and mixtures. Annex III contains the list of hazard statements, supplemental hazard information, and supplemental label elements. Annex V lists the hazard pictograms. Annex VI contains the harmonized classification and labelling for certain hazardous substances. Annex VII provides a table of translation from classification under Directive 67/548/EEC to classification under the CLP Regulation.
For substances and mixtures placed on the market, the classification requirements bind 'manufacturers, importers and downstream users' [Article 1 (b) (i)], whereas the labelling and packaging requirements bind 'suppliers' [Article 1 (b) (ii)]. Certain substances are exempt from the CLP Regulation, such as radioactives [Article 1 (2) (a)] and those falling under specific regulations, such as medicinal products, cosmetics, and foodstuffs [Article 1 (4)]. This leads to inconsistent labelling requirements for substances falling under specific regulations, e.g. cosmetics, medicaments, or medical devices, with the last of these frequently representing a black box regarding ingredients to be identified in the patch test clinics. With specific regulations not being consistently harmonized, the lack of a horizontal approach to hazard identification and risk assessment at the European level may occur, as illustrated by the methylisothiazolinone fiasco. Article 2 provides definitions of terms within the CLP Regulation. Articles 5 and 6 define the relevant available information for the purposes of determining whether a substance or a mixture poses a physical, health or environmental hazard. These information sources include data generated in accordance with methods defined in Article 8 (3), epidemiological and human data, any other information generated in accordance with section 1 of Annex XI The European Chemical Agency (ECHA) issued a 'Guidance on the Application of the CLP Criteria', to assist, primarily, manufacturers or importers in applying classification and labelling criteria (10) , which itself comprises 662 pages. However, this document 'does not constitute legal advice', as stated in the Legal Notice; it is not legally binding, and will not assist those bound by the Regulation to classify products when challenged in courts.
The Concepts of Hazard, Risk, Hazard Identification, and Risk Characterization
In order to understand the CLP Regulation, an understanding of the terms 'hazard', 'risk', 'hazard identification' and 'risk characterization' is necessary. Chemicals that are potentially noxious to human health or the environment may constitute a hazard, but, for a risk to be present, exposure is necessary. Thus, risk is represented by the equation: risk = hazard × exposure. Hazard identification refers to the identification of potentially noxious chemicals, for example by sensitization assays. Hazard characterization is the ranking of noxious properties in terms of potency. Risk characterization, then, refers not only to the potency of noxious properties, but especially to the modes and probabilities of exposure.
Classification and Misclassification of Chemicals According to the CLP Regulation
Classification of chemical substances and mixtures is performed according to specific classification criteria (algorithmic approach). Provided that these criteria are fulfilled, the substance and mixture has to be classified into a specific category, with the resulting requirement to label it with a pictogram, a signal word, a hazard statement, and precautionary statements referring to prevention, response, storage, and disposal. Categories of special interest to dermatologists are skin corrosion (Hazard Statement H314: Causes severe skin burns and eye damage), skin irritation (Hazard Statement H315: Causes skin irritation), and skin sensitization (Hazard Statement H317: May cause an allergic skin reaction). These hazard statements are part of the GHS, and are intended to replace the well-known R-phrases.
For instance, a substance or mixture is categorized as 'skin corrosive' if it is a substance that, in an animal test, produces destruction of skin tissue, namely, visible necrosis through the epidermis and into the dermis, in at least 1 tested animal after exposure for up to 4 h (11). In contrast, a substance or mixture is categorized as 'skin irritant' if it produces reversible damage to the skin following application for up to 4 h. If neither event occurs, the substance or mixture is not classified. In practice, the classification procedure may be a rather complicated algorithm, as straightforward results of animal experiments are frequently not available, and tests on animals are discouraged by the CLP Regulation (12) . Tests on non-human primates are explicitly prohibited for the purposes of the CLP Regulation.
Physicians, in particular dermatologists and occupational physicians, should take into account that misclassification may occur in two ways:
• A substance or mixture could be 'underclassified', that is, not classified if, in fact, it would need to be classified, or could be falsely classified in a lower category, if, in fact, it would need to be classified in a higher category.
• On the other hand, a substance or mixture could be 'overclassified', that is, classified if, in fact, it would need not to be classified, or falsely classified in a higher category, if, in fact, it would need to be classified in a lower category.
Both types of misclassification may be detrimental to the aims of consumer protection:
• An underclassification would falsely lead a consumer to underestimate the actual hazard of a substance or mixture, thus possibly leading to unprotected exposure with negative health effects.
• On the other hand, an overclassification, although possibly not leading to an unsafe exposure, might lead to unnecessary and costly prevention measures. (16) , which requires that no producer shall place a product on the market unless the product is a safe product [Article 5 (1)]. In the context of the GPS Regulations, a 'safe product' is defined as 'a product which, under normal or reasonably foreseeable conditions of use including duration and, where applicable, putting into service, installation and maintenance requirements, does not present any risk or only the minimum risks compatible with the product's use, considered to be acceptable and consistent with a high level of protection for the safety and health of persons'. Furthermore, under Article 7 (1) of the GPS Regulations, 'a producer shall provide consumers with the relevant information to enable them (i) to assess the risks inherent in a product throughout the normal or reasonably foreseeable period of its use, where such risks are not immediately obvious without adequate warnings, and (ii) to take precautions against those risks'. Considering the classification and labelling of chemical substances and mixtures, the provision of misinformation to consumers by false classification and labelling might be an offence under Article 7 (1) of the GPS Regulations. Enforcement of the GPS Regulations is the duty of the enforcement authorities [(Article 10 (1)], namely, the local Trading Standards offices. Furthermore, the GPS Regulations provide for complaints procedures (Article 37), under which 'complaints may be submitted by any person on product safety and on surveillance and control activities, which complaints shall be followed up as appropriate'. This gives a right to consumers and dermatologists to report unsafe products in the market.
Non-conformity Reporting to the European Commission
Dangerous non-food consumer products have to be reported by the national authorities to the EU under Article 5 (3) of the GPS Regulations 2005 (16), where they are entered into the Rapid Alert System for Dangerous Non-food Products (RAPEX) notifications, and they are published regularly on the Commission website to inform the public (17) . The information may also be derived from producers or distributors who organize recalls of the products that they have found to pose a risk to consumers' health. A search in the RAPEX system for 'CLP' and 'notifying country = any', 'product = chemical' If dermatologists identify a dangerous product that is inadequately labelled, they should inform their national authority for evaluation and notification of the Commission to have it entered into the RAPEX database. However, considering that the national poison centre data range in the hundreds of thousands of reported events, the low number of reports in the RAPEX system may indicate considerable underreporting through this channel.
Shortcomings and Suggestions for Reform
Considering the complexity of the CLP Regulation, it may be assumed that both manufacturers and enforcing authorities may struggle to consistently comply with this legislation. This problem is increased by the delegation of the task of enforcing the CLP Regulation to Member States, who may perform this task in a non-uniform way.
Suggestions for reform will have to focus on a reduction in the complexity of the CLP Regulation, which would be the duty of the Commission, as it has to initiate and review secondary legislation under the Treaties.
The ECHA accumulates the expert knowledge to detect misclassifications; however, sufficient manpower is necessary at the national and European levels to actually screen products on the markets of the Member States and to inform Member States about findings of misclassifications, to strengthen their ability to take immediate enforcement action. As a second, more far-reaching reform, consideration could be given to partially transferring the duty to enforce the CLP Regulation from the Member States to a European Agency, in this case to the ECHA.
Finally, enforcement of the CLP Regulation may occur indirectly through actions taken by consumers against A dermatologist encountering a product not complying with the CLP Regulation should proceed to inform the competent national authority in charge; this information may be transmitted in an informal letter, email, fax, or telephone call. A list of the national CLP-competent authorities is shown in Table 1 .
Conclusion
The objective of the CLP Regulation is to ensure a classification of possibly hazardous chemical substances and mixtures, in order for their hazards to be properly identified and communicated, thus allowing consumers to take appropriate measures to protect themselves from the possibly damaging effects. Manufacturers are required by the CLP Regulation to classify their products according to the rules given in the CLP Regulation, aided by the ECHA Guidance. The duty of enforcing the CLP Regulation lies with the Member States. The fact that only a few cases of non-compliance with the CLP Regulation are being reported through the RAPEX system may either indicate a high compliance, or reflect a lack of inspections assessing not only classification and labelling as such, but also their appropriateness, considering that the classification procedure is highly complex, requiring expert knowledge. In practice, enforcement actions by the competent authorities, but also claims under civil law by consumers, may be hindered by the lack of resources and manpower of the competent authorities, the sheer complexity of the CLP Regulation, and unawareness of the ramifications of the CLP Regulation by consumer associations and the public at large. From a dermatological point of view, suggestions for improvement therefore include strengthening of the manpower of national and European authorities so that they are able to closely monitor compliance with the above-mentioned regulations, the dissemination of knowledge and information to dermatologists and consumers regarding their rights under the CLP Regulation, consideration of revision of the CLP Regulation to reduce its complexity, and improved enforcement by enabling the ECHA to play a greater role in the detection of cases of non-compliance. Dermatologists encountering products that do not comply with the CLP Regulation should inform the competent national authorities, so that the products can be entered into the RAPEX database of the European Commission. See Table 2 for 'learning points' for dermatologists.
